Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 2, 2026, 3:20 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 55 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Placebo vaginal gel Clear all
Completed Phase 1 Interventional Accepts healthy volunteers

Safety, Pharmacokinetics and Acceptability of PC-1005 for Vaginal Use

NCT02033109
View directory record Official record
Conditions
HIV
Interventions
PC-1005, HEC gel
Drug
Lead sponsor
Population Council
Other
Eligibility
19 Years to 49 Years · Female only
Enrollment
35 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2015
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated Aug 15, 2017 · Synced Oct 2, 2026, 3:20 PM EDT
Withdrawn Phase 1 Interventional Accepts healthy volunteers

Safety and Acceptability of Tenofovir 1% Gel in Adolescent Females

NCT02245945
View directory record Official record
Conditions
HIV Prevention
Interventions
TFV 1% vaginal gel, HEC Placebo Gel
Drug
Lead sponsor
CONRAD
Other
Eligibility
15 Years to 17 Years · Female only
Healthy volunteers
Accepts healthy volunteers
U.S. locations
2
States / cities
The Bronx, New York • Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated May 1, 2015 · Synced Oct 2, 2026, 3:20 PM EDT
Withdrawn Phase 2Phase 3 Interventional Accepts healthy volunteers

Vaginal Progesterone in Twins With Short Cervix

NCT01812239
View directory record Official record
Conditions
Premature Birth
Interventions
Vaginal Progesterone gel., fetal fibronectin swab., Placebo gel
Drug · Procedure
Lead sponsor
Obstetrix Medical Group
Industry
Eligibility
18 Years to 60 Years · Female only
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2018
U.S. locations
1
States / cities
San Jose, California
Source: ClinicalTrials.gov public record
Updated Dec 19, 2014 · Synced Oct 2, 2026, 3:20 PM EDT
Terminated Phase 1 Interventional Accepts healthy volunteers

Alprostadil (FemLife Gel) in the Treatment of Female Sexual Arousal Disorder

NCT00572377
View directory record Official record
Conditions
Female Sexual Arousal Disorder
Interventions
FemLife Gel, Placebo
Drug
Lead sponsor
Cedars-Sinai Medical Center
Other
Eligibility
Female only
Enrollment
10 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2008
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Jun 20, 2008 · Synced Oct 2, 2026, 3:20 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Development of Adherence Biomarkers for Multiple Microbicide and Multipurpose Prevention Technology (MPT) Dosage Forms

NCT02569697
View directory record Official record
Conditions
HIV
Interventions
HEC Placebo gel, Placebo Intravaginal Ring, Placebo Vaginal Film, Placebo Vaginal Insert
Other
Lead sponsor
CONRAD
Other
Eligibility
18 Years to 50 Years · Female only
Enrollment
50 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2016
U.S. locations
1
States / cities
Norfolk, Virginia
Source: ClinicalTrials.gov public record
Updated Sep 2, 2016 · Synced Oct 2, 2026, 3:20 PM EDT
Completed Phase 3 Interventional

Subcutaneous Progesterone in Frozen- Thawed Single Euploid Blastocyst Transfer.

NCT04549116
View directory record Official record
Conditions
Infertility
Interventions
Progesterone-IBSA Injectable Solution, Progesterone Vaginal Gel with Applicator, Placebo Vaginal gel with applicator, Placebo injectable solution
Drug
Lead sponsor
IBSA Institut Biochimique SA
Industry
Eligibility
35 Years to 42 Years · Female only
Enrollment
688 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
24
States / cities
Tempe, Arizona • Encino, California • Los Angeles, California + 20 more
Source: ClinicalTrials.gov public record
Updated Aug 27, 2026 · Synced Oct 2, 2026, 3:20 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Efficacy and Safety Study of Lidocaine Vaginal Gel for Recurrent Dysmenorrhea (Painful Periods)

NCT00651313
View directory record Official record
Conditions
Dysmenorrhea
Interventions
Lidocaine, Placebo
Drug
Lead sponsor
Juniper Pharmaceuticals, Inc.
Industry
Eligibility
18 Years to 40 Years · Female only
Enrollment
81 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2008
U.S. locations
4
States / cities
Winston-Salem, North Carolina • Memphis, Tennessee • Austin, Texas + 1 more
Source: ClinicalTrials.gov public record
Updated Feb 17, 2012 · Synced Oct 2, 2026, 3:20 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Compare Three Different Formulations of Tenofovir 1% Gel When Administered Rectally

NCT01575405
View directory record Official record
Conditions
HIV Prevention
Interventions
Rectal formulation (RF) of tenofovir 1% gel, Vaginal formulations (original VF and reduced vaginal glycerin formulation RGVF) of tenofovir 1% gel, Universal HEC Placebo Gel Formulation
Drug
Lead sponsor
Ian McGowan
Other
Eligibility
18 Years and older
Enrollment
13 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013
U.S. locations
2
States / cities
Los Angeles, California • Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Nov 7, 2013 · Synced Oct 2, 2026, 3:20 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Duration of Effect of Acidform Gel on Vaginal pH

NCT02693418
View directory record Official record
Conditions
Healthy
Interventions
Acidform 5 g, Placebo 4 g, Acidform 4 g, Acidform 3 g
Drug
Lead sponsor
Evofem Inc.
Industry
Eligibility
18 Years to 45 Years · Female only
Enrollment
105 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016
U.S. locations
2
States / cities
Baltimore, Maryland • Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Nov 20, 2020 · Synced Oct 2, 2026, 3:20 PM EDT
Terminated Phase 4 Interventional Accepts healthy volunteers

Prevention of Recurrent UTI Using Vaginal Testosterone Versus Placebo Placebo

NCT04807894
View directory record Official record
Conditions
Recurrent Urinary Tract Infection, Vaginal Atrophy, Postmenopausal Disorder
Interventions
Vaginal Cream with Applicator
Drug
Lead sponsor
Jefferson Drapkin
Other
Eligibility
60 Years to 90 Years · Female only
Enrollment
67 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2026
U.S. locations
1
States / cities
Brooklyn, New York
Source: ClinicalTrials.gov public record
Updated Sep 17, 2026 · Synced Oct 2, 2026, 3:20 PM EDT
Completed Phase 2Phase 3 Interventional Accepts healthy volunteers Results available

Phase 2B/3 Double-blinded Placebo-controlled

NCT03107377
View directory record Official record
Conditions
Chlamydia Trachomatis Infection
Interventions
EVO100, Placebo
Drug
Lead sponsor
Evofem Inc.
Industry
Eligibility
18 Years to 45 Years · Female only
Enrollment
860 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2019
U.S. locations
50
States / cities
Mobile, Alabama • Phoenix, Arizona • Tucson, Arizona + 40 more
Source: ClinicalTrials.gov public record
Updated Aug 12, 2020 · Synced Oct 2, 2026, 3:20 PM EDT
Not listed Phase 1 Interventional Accepts healthy volunteers

An Imaging Trial of the Distribution of Topical Gel in the Human Vagina: Assessment of Bare Spots

NCT00214812
View directory record Official record
Conditions
HIV Infections
Interventions
HEC placebo gel
Drug
Lead sponsor
Biosyn
Industry
Eligibility
18 Years to 45 Years · Female only
Enrollment
6 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
Started 2005
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Oct 25, 2005 · Synced Oct 2, 2026, 3:20 PM EDT
Withdrawn Phase 2 Interventional Accepts healthy volunteers

Carrageenan-Containing Gel in Reducing the Rate of HPV Infection in Healthy Participants

NCT02382419
View directory record Official record
Conditions
Healthy Subject, Human Papillomavirus Infection
Interventions
carrageenan-containing gel, Placebo, Laboratory Biomarker Analysis, Questionnaire Administration
Drug · Other
Lead sponsor
Rutgers, The State University of New Jersey
Other
Eligibility
19 Years to 35 Years · Female only
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2019
U.S. locations
1
States / cities
Newark, New Jersey
Source: ClinicalTrials.gov public record
Updated Aug 1, 2019 · Synced Oct 2, 2026, 3:20 PM EDT
Completed Phase 3 Interventional Results available

The Vaginal Health Trial

NCT02516202
View directory record Official record
Conditions
Atrophy of Vagina, Menopause, Dyspareunia (Female)
Interventions
Vagifem, Replens, Placebo tablet, Placebo gel
Drug · Device · Other
Lead sponsor
Fred Hutchinson Cancer Center
Other
Eligibility
45 Years to 70 Years · Female only
Enrollment
302 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
2
States / cities
Minneapolis, Minnesota • Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Jul 12, 2018 · Synced Oct 2, 2026, 3:20 PM EDT
Completed Phase 3 Interventional Results available

Study Evaluating the Equivalence of GDC-229 and Metronidazole Vaginal Gel 0.75% in the Treatment of Bacterial Vaginosis

NCT03091777
View directory record Official record
Conditions
Bacterial Vaginosis
Interventions
GDC-229, Metronidazole Vaginal Gel 0.75%, Placebo
Drug
Lead sponsor
Balmoral Medical company
Industry
Eligibility
18 Years and older · Female only
Enrollment
871 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
1
States / cities
Raleigh, North Carolina
Source: ClinicalTrials.gov public record
Updated Jan 7, 2020 · Synced Oct 2, 2026, 3:20 PM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Self-Administered Lidocaine Gel for Pain Management With IUD Insertion

NCT02738203
View directory record Official record
Conditions
IUD Insertion
Interventions
Vaginal 2% Lidocaine, Surgical Lubricant Jelly
Drug
Lead sponsor
Stanford University
Other
Eligibility
18 Years and older · Female only
Enrollment
220 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2017
U.S. locations
1
States / cities
Palo Alto, California
Source: ClinicalTrials.gov public record
Updated Jun 6, 2019 · Synced Oct 2, 2026, 3:20 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Phase I Trial to Assess the Safety of Tenofovir Gel and Film Formulations: FAME 04

NCT01989663
View directory record Official record
Conditions
HIV
Interventions
1% vaginally applied tenofovir gel, Tenofovir film- 10mg, Tenofovir Film-40 mg, HEC Placebo Gel, Placebo Vaginal Film
Drug · Other
Lead sponsor
CONRAD
Other
Eligibility
18 Years to 45 Years · Female only
Enrollment
78 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2015
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jul 27, 2016 · Synced Oct 2, 2026, 3:20 PM EDT
Completed Phase 4 Interventional Results available

Effect of Tenofovir on Genital Herpes Simplex Virus (HSV) Shedding

NCT01448616
View directory record Official record
Conditions
Herpes Simplex Type II
Interventions
TDF, Placebo Vaginal Gel, Vaginal TFV Gel, Placebo Tablets
Drug
Lead sponsor
University of Washington
Other
Eligibility
18 Years to 50 Years · Female only
Enrollment
73 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2015
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Feb 16, 2023 · Synced Oct 2, 2026, 3:20 PM EDT
Completed Phase 3 Interventional Results available

DARE-BV1 in the Treatment of Bacterial Vaginosis (DARE-BVFREE)

NCT04370548
View directory record Official record
Conditions
Bacterial Vaginosis
Interventions
DARE-BV1clindamycin phosphate vaginal gel, 2%
Drug
Lead sponsor
Daré Bioscience, Inc.
Industry
Eligibility
12 Years and older · Female only
Enrollment
307 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020
U.S. locations
10
States / cities
Tucson, Arizona • Denver, Colorado • Miami, Florida + 6 more
Source: ClinicalTrials.gov public record
Updated Dec 8, 2022 · Synced Oct 2, 2026, 3:20 PM EDT
Completed Phase 3 Interventional Results available

Prasterone (Dehydroepiandrosterone) in Treating Postmenopausal Cancer Survivors With Vaginal Symptoms

NCT01376349
View directory record Official record
Conditions
Breast Cancer, Gynecologic Cancer
Interventions
prasterone, placebo
Drug · Other
Lead sponsor
Alliance for Clinical Trials in Oncology
Other
Eligibility
18 Years and older · Female only
Enrollment
464 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2017
U.S. locations
280
States / cities
Scottsdale, Arizona • Aurora, Colorado • Boulder, Colorado + 185 more
Source: ClinicalTrials.gov public record
Updated Feb 7, 2019 · Synced Oct 2, 2026, 3:20 PM EDT
Withdrawn Not applicable Interventional

Vaginal Progesterone as a Treatment for Women Active Preterm Labor

NCT01206998
View directory record Official record
Conditions
Labor, Premature
Interventions
Vaginal progesterone gel, Placebo vaginal gel
Drug
Lead sponsor
University of Rochester
Other
Eligibility
18 Years and older · Female only
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010
U.S. locations
1
States / cities
Rochester, New York
Source: ClinicalTrials.gov public record
Updated Oct 1, 2012 · Synced Oct 2, 2026, 3:20 PM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety Study of SPL7013 Gel to Prevent the Recurrence of Bacterial Vaginosis (BV)

NCT02237950
View directory record Official record
Conditions
Bacterial Vaginosis
Interventions
Metronidazole oral tablets 500mg, 1% SPL7013 Gel, Placebo gel
Drug
Lead sponsor
Starpharma Pty Ltd
Industry
Eligibility
16 Years to 45 Years · Female only
Enrollment
586 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
37
States / cities
Birmingham, Alabama • Montgomery, Alabama • Little Rock, Arkansas + 32 more
Source: ClinicalTrials.gov public record
Updated Jul 22, 2019 · Synced Oct 2, 2026, 3:20 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Safety and Acceptability Study of the UC-781 Microbicide Gel Applied Rectally

NCT00408538
View directory record Official record
Conditions
HIV Infections
Interventions
UC-781 microbicide gel (0.1% and 0.25%), placebo
Drug
Lead sponsor
University of California, Los Angeles
Other
Eligibility
18 Years and older
Enrollment
36 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2008
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated May 4, 2009 · Synced Oct 2, 2026, 3:20 PM EDT
Completed Phase 1Phase 2 Interventional Accepts healthy volunteers Results available

A Safety Study of Two Dapivirine (TMC120) Vaginal Gels in the United States

NCT00799058
View directory record Official record
Conditions
HIV-1 Infections
Interventions
dapivirine 4789, dapivirine gel 4759, Drug placebo
Drug
Lead sponsor
International Partnership for Microbicides, Inc.
Industry
Eligibility
18 Years to 40 Years · Female only
Enrollment
128 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2011
U.S. locations
5
States / cities
Birmingham, Alabama • Torrance, California • Chicago, Illinois + 2 more
Source: ClinicalTrials.gov public record
Updated Oct 25, 2022 · Synced Oct 2, 2026, 3:20 PM EDT